Concept

Selective receptor modulator

In the field of pharmacology, a selective receptor modulator or SRM is a type of drug that has different effects in different tissues. A SRM may behave as an agonist in some tissues while as an antagonist in others. Hence selective receptor modulators are sometimes referred to as tissue selective drugs or mixed agonists / antagonists. This tissue selective behavior is in contrast to many other drugs that behave either as agonists or antagonists regardless of the tissue in question. Note that selective estrogen receptor modulator (SERM) is the only class of these drugs currently on the market in the US.

Official source

https://en.wikipedia.org/wiki/Selective_receptor_modulator

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related lectures (1)

Nuclear Receptors: Coactivators and Transcriptional Modulation Log in to Mediaspace to watch this video

Explores coactivators' role in transcriptional modulation, histone acetylation, ERa antagonists, and tissue-specific actions of nuclear receptors.

Related concepts (1)

Selective androgen receptor modulator

Selective Androgen Receptor Modulators or SARMs are a class of androgen receptor ligands that were developed with the intention of maintaining some of the desirable effects of androgens, such as preventing osteoporosis and muscle loss while reducing risks of undesirable conditions such as prostate cancer. In the late 1990s, the first nonsteroidal SARM, an analog of bicalutamide, was discovered at Imperial Chemical Industries.

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Official source

https://en.wikipedia.org/wiki/Selective_receptor_modulator

About this result

Related lectures (1)

Nuclear Receptors: Coactivators and Transcriptional Modulation Log in to Mediaspace to watch this video

Explores coactivators' role in transcriptional modulation, histone acetylation, ERa antagonists, and tissue-specific actions of nuclear receptors.

Related publications (3)

Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers

Women with germline BRCA1 pathogenic variants face a very high risk of early-onset triple-negative breast cancer (TNBC), with risk-reducing mastectomy currently the only established preventive option. Emerging evidence suggests aberrant progesterone signalling contributes to TNBC risk, while preclinical studies indicate progesterone receptor modulators such as mifepristone may substantially reduce cancer development. DNA methylation-based markers reflecting field cancerization and replicative age could enab

Nature Research2026

Balancing bistable perception during self-motion

In two experiments we investigated whether bistable visual perception is influenced by passive own body displacements due to vestibular stimulation. For this we passively rotated our participants around the vertical (yaw) axis while observing different rotating bistable stimuli (bodily or non-bodily) with different ambiguous motion directions. Based on previous work on multimodal effects on bistable perception, we hypothesized that vestibular stimulation should alter bistable perception and that the effects

Springer2012

Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor - Synthesis and pharmacological evaluation of a Y2 antagonist

Neuropeptide Y (NPY) is a potent inhibitor of neurotransmitter release through the Y2 receptor subtype. Specific antagonists for the Y2 receptors have not yet been described, Based on the concept of template-assembled synthetic proteins we have used a cyclic template molecule containing two p-turn mimetics for covalent attachment of four COOH-terminal fragments RQRYNH(2) (NPY 33-36), termed T-4-NPY(33-36). This structurally defined template-assembled synthetic protein has been tested for binding using

1997

Related people (4)

Kristina Schoonjans

Expertise Bile acid signalingNutrient sensingIntermediary metabolismMetabolic disorders Teaching & PhD PhD Students Adrien Faure Past EPFL PhD Students Pan Xu, Ece Yildiz, Nadia Bresciani, Yu Sun, Francesca Pontanari, Alejandro Alonso Calleja Past EPFL PhD Students as codirector Mitsunori Nomura, Pan Xu, Katyayanee Neopane, Lucie Camille Chanvillard, Jakob Josef Langer, Bilge Sen Elçi Courses General Biology BIOENG-110 The purpose of the course is to provide a general overview of the biolo

Johan Auwerx

Johan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways. Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards. Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.

Friedhelm Christoph Hummel

Expertise Stroke recovery Healthy Aging Motor Control Motor Learning Cognitive Control Neuroplasticity Non-invasive Brain Stimulation Structural and functional Neuroimaging Connectivity Postal Address Campus Biotech Defitech Chair of Clinical Neuroengineering Brain Mind Institute, SV Neuro X Institute, Swiss Federal Institute of Technology EPFL Campus Biotech Rm H4.3.132.084, 9, Chemin des Mines 1202 Geneva Teaching & PhD PhD Students Maria Ploumitsakou, Simona Losacco, Fabienne Windel, Andrea Protani, Sta

Takuya Morishita